US 12,410,175 B2
Compounds
Peng Li, New Milford, NJ (US); and Robert Davis, San Diego, CA (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Appl. No. 17/753,472
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
PCT Filed Sep. 3, 2020, PCT No. PCT/US2020/049141
§ 371(c)(1), (2) Date Mar. 3, 2022,
PCT Pub. No. WO2021/046179, PCT Pub. Date Mar. 11, 2021.
Claims priority of provisional application 62/895,477, filed on Sep. 3, 2019.
Prior Publication US 2022/0356187 A1, Nov. 10, 2022
Int. Cl. C07D 487/14 (2006.01); A61K 38/00 (2006.01)
CPC C07D 487/14 (2013.01) [A61K 38/005 (2013.01)] 7 Claims
 
1. A compound according to Formula Ia:

OG Complex Work Unit Chemistry
wherein
(i) R2 and R5 are independently H or hydroxy and R3 and R4 together form a tri- or tetra-methylene bridge;
(ii) R6 is (optionally halo-substituted or hydroxy-substituted) phenylamino, (optionally halo-substituted or hydroxy-substituted) benzylamino, C1-4alkyl, or C1-4alkyl sulfide;
(iii) R10 is C1-4alkyl, methylcarbonyl, hydroxyethyl, carboxylic acid, sulfonamide, (optionally halo- or hydroxy-substituted) phenyl, (optionally halo- or hydroxy-substituted) pyridyl, or thiadiazolyl; and
X and Y are independently C or N,
wherein at least one of R2 and R5 are hydroxy,
optionally wherein at least one carbon atom is substituted with Carbon-14 ([14C]),
in free or pharmaceutically acceptable salt form, or its enantiomers, diastereoisomers or racemates.